BDTX
Black Diamond Therapeutics, Inc.
17
Building
BDTX's irreversible small molecule inhibitor, BDTX-189, makes it compelling amid biotech risk rotation.
The thesis
Black Diamond Therapeutics operates in biotechnology, developing therapeutic agents for genetically characterized tumors. The company's conviction score is 17/100, indicating medium conviction. Analyst consensus rating is BUY, but the P/E ratio is -3.0x, indicating significant losses. The DCF intrinsic value is $11, suggesting potential undervaluation.
Why now
The current macro context, with geopolitical tensions and market volatility, makes biotech stocks like BDTX more sensitive to risk rotation. The inactive risk_off_rotation driver indicates a potential catalyst for change.
What to watch
Progress on BDTX-189's clinical trials and updates on the company's financials will be key indicators to confirm or deny the thesis. Changes in the analyst consensus rating and conviction score will also be important to monitor.
Key risks
Execution risk is high due to the early stage of BDTX-189's development, and valuation risk is significant given the -3.0x P/E ratio. Macro risk is also present due to the current geopolitical tensions and market volatility.
Theme exposure
Healthcare, Biotech & Devices
DirectBlack Diamond Therapeutics, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.